B Capital Selected by AMED as Registered VC to Advance Japan’s Drug Development Ecosystem
B Capital, a multi-stage investment firm with a strong focus on healthcare innovation, has announced that it has been officially selected as a registered venture capital firm under a key initiative led by the Japan Agency for Medical Research and Development. The designation comes through AMED’s Strengthening Program for Pharmaceutical Startup Ecosystem, a government-backed effort aimed at fostering innovation and accelerating the growth of Japan’s pharmaceutical and biotechnology startup landscape.
This recognition marks an important milestone for B Capital as it continues to expand its footprint in global healthcare investing, particularly within the Asia-Pacific region. As a registered venture capital partner under the AMED program, B Capital is now positioned to both invest in and actively support pharmaceutical and biotech startups in Japan, including playing a role in their commercialization strategies. The designation effectively integrates the firm into a broader national effort to nurture early-stage innovation and translate scientific discoveries into viable therapeutic solutions.
The Strengthening Program for Pharmaceutical Startup Ecosystem is a cornerstone initiative designed to enhance Japan’s competitiveness in drug discovery and development. Through this program, AMED provides financial support in the form of subsidies to startups focused on pharmaceutical innovation, particularly those engaged in early-stage drug discovery. The goal is to strengthen the underlying infrastructure of Japan’s biotech ecosystem, enabling startups to progress from foundational research through preclinical development and into clinical-stage programs.
In addition to funding, AMED maintains a curated registry of venture capital firms that have demonstrated a proven track record of investing in and supporting pharmaceutical startups. Inclusion in this registry is a mark of credibility and expertise, as it signifies that the selected firms possess the necessary experience to guide companies through the complex and resource-intensive process of drug development. These firms are expected not only to provide capital but also to offer strategic guidance, operational support, and industry connections that can accelerate growth and increase the likelihood of success.
Japan has long been recognized as a hub of scientific excellence, with a strong foundation in biomedical research and a highly skilled workforce. In recent years, the country has also seen a growing wave of entrepreneurial activity in the life sciences sector, with an increasing number of startups emerging from academic institutions and research centers. These companies are working on cutting-edge technologies across areas such as biotechnology, medtech, and data-driven healthcare, positioning Japan as a key player in the global innovation landscape.
B Capital’s participation in the AMED program reflects its belief that the next generation of breakthrough therapies will increasingly originate from Japan and the broader Asia-Pacific region. By engaging directly with local startups, the firm aims to help bridge the gap between early-stage scientific discovery and global commercialization. This includes providing not only financial investment but also hands-on support in areas such as clinical development strategy, regulatory navigation, and market access.
Raj Ganguly, Co-Founder and Co-CEO of B Capital, described the selection as a significant step forward in the firm’s healthcare investment strategy. He emphasized that Japan represents a uniquely attractive market, combining world-class scientific research with a new generation of ambitious entrepreneurs. According to Ganguly, B Capital is honored to support these founders as they work to transform innovative science into therapies that can benefit patients both domestically and internationally.
Echoing this sentiment, Robert Mittendorff, MD, General Partner and Global Head of Healthcare at B Capital, highlighted the importance of sustained investment in therapeutic innovation. He noted that the global healthcare landscape is experiencing an unprecedented wave of scientific advancement, driven by new technologies such as artificial intelligence, precision medicine, and advanced biologics. In this context, both public and private sector investment will be critical to ensuring that promising discoveries are successfully translated into approved treatments.
Mittendorff also pointed to B Capital’s extensive experience in supporting pharmaceutical and AI-enabled drug discovery companies as a key strength. With the added recognition from AMED, the firm is well-positioned to contribute meaningfully to the development and commercialization of new therapies within Japan’s ecosystem. This includes leveraging its global network and expertise to help startups scale their operations and reach international markets.
From a regional perspective, Kelly Qiao, PhD, Senior Principal at B Capital, emphasized the unique characteristics of Japan’s pharmaceutical ecosystem. Based on the firm’s experience across Asia, she noted that Japan stands out for its scientific rigor and the increasing ambition of its startup community. There is a growing convergence of disciplines, particularly at the intersection of biotechnology, medical technology, and data-driven healthcare solutions.
Qiao explained that this convergence is creating new opportunities for innovation, as strong foundational research is increasingly paired with a focus on translational and clinical applications. The AMED designation enables B Capital to engage more closely with startups at the point where promising science is ready to scale, providing the resources and guidance needed to move from discovery to commercialization. This approach aligns with the firm’s long-term, global perspective on healthcare investing.
Since its inception, B Capital has built a robust portfolio of healthcare investments, supporting more than 50 startups across a range of sectors, including digital health, biotechnology, medtech, and health-tech platforms. This experience has equipped the firm with deep insights into the challenges and opportunities associated with building successful healthcare companies, from early-stage research through to market entry and beyond.
Looking ahead, B Capital intends to leverage its AMED certification to deepen its engagement with Japan’s pharmaceutical startup community. This includes identifying high-potential companies at the earliest stages of development and providing them with the capital, expertise, and strategic support needed to succeed. By partnering with founders from the outset, the firm aims to play a pivotal role in shaping the future of drug discovery and development in Japan.
In summary, B Capital’s selection as a registered venture capital firm under AMED’s Strengthening Program for Pharmaceutical Startup Ecosystem represents a significant development for both the firm and Japan’s life sciences sector. By combining government support with private investment and global expertise, the initiative has the potential to accelerate innovation and bring new therapies to patients more efficiently. As B Capital expands its activities in Japan, its involvement is expected to contribute to the continued growth and global impact of the country’s pharmaceutical startup ecosystem.
About B Capital
B Capital is a multi-stage global investment firm that partners with extraordinary entrepreneurs to shape the future through technology. With more than $11 billion in assets under management across multiple funds, the firm focuses on seed to late-stage venture growth investments, primarily in the Technology, Healthcare and Energy sectors. Founded in 2015, B Capital leverages an integrated team across nine locations in the US and Asia, as well as a strategic partnership with BCG, to provide the value-added support entrepreneurs need to scale quickly and efficiently, expand into new markets and build exceptional companies.
Source Link:https://www.businesswire.com/
